BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced the appointment of Jamieson Bondarenko, CFA, CMT, to the company’s Board of Directors. Through his merchant capital company, JGRNT Capital Corp., Bondarenko currently offers strategic capital markets and corporate development advice to early-stage life sciences companies. He has also served as Principal, Managing Director of Equity Capital Markets at Eight Capital and Equity Capital Markets as well as Investment Banking positions at Dundee Capital Markets, Wellington West Capital Markets and HSBC Securities. “Jamieson brings extensive capital markets experience to BriaCell,” BriaCell Chairman Dr. Saeid Babaei stated in the news release. “His expertise will be a valuable resource for BriaCell in the current investment environment as we execute our mission to bring innovative therapeutics to patients who tirelessly fight the deadliest forms of advanced breast cancer with no effective treatment options.”
To view the full press release, visit http://ibn.fm/7iocx
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.